's () Lammert Albers talks to Proactive London about landing three new contracts, with three different customers in the area of Alzheimer's disease.
Albers talks through each of the projects, which includes a phase I study, an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial.
Albers also highlights the importance of the CTAD and the Aducanumab advisory committee meeting this Friday, which will take place virtually this year.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE